Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset
Merck KGaA (Germany) plans to acquire Silence Therapeutics, a UK-based biotech company, to strengthen its rare disease pipeline. The acquisition focuses on Divesiran, an siRNA therapy for polycythemia vera that met its primary endpoint in a Phase 2 trial, with an 88% responder rate. The deal is expected to close in Q1 2027, subject to regulatory approvals and shareholder approval. Merck will fund the acquisition through new debt.
How this was made
The 30-second read
Why it matters
The acquisition expands Merck's rare‑disease pipeline and adds a potentially best‑in‑class therapy, likely influencing Merck's valuation and sector sentiment.
Market read
A major M&A move in the biotech space that could shift investor focus toward rare‑disease therapeutics.
What to watch
Regulatory approval risk and integration challenges for a German pharma acquiring a UK biotech.
Background
Merck KGaA announced a planned acquisition of Silence Therapeutics, a UK‑based biotech with an ADS listed on NASDAQ, to acquire its siRNA asset Divesiran.
Market effects
Potential boost to biotech and rare disease sector as Merck KGaA expands its siRNA pipeline.
European pharma market may see increased M&A activity following this deal.
Global investors may reprice other rare‑disease biotech stocks.
Counterpoint
Deal could be overvalued if Phase 3 data for Divesiran fails to meet expectations.
Key entities
- CompanyMerck KGaA
German science and technology company acquiring Silence Therapeutics.
- CompanySilence Therapeutics
UK biotech with siRNA asset Divesiran, listed via ADS on NASDAQ.
